111 Capital Vaxcyte, Inc. Transaction History

111 Capital

$582 Billion
Q2 2025

A detailed history of 111 Capital transactions in Vaxcyte, Inc. stock. As of the latest transaction made, 111 Capital holds 10,991 shares of PCVX stock, worth $392,598. This represents 0.06% of its overall portfolio holdings.

Number of Shares

10,991

Holding current value

$392,598

% of portfolio

0.06%

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2025 Jul 21, 2025	BUY	$28.04 - $37.2 $308,187 - $408,865	10,991 New	10,991 $357 Million

Others Institutions Holding PCVX

# of Institutions

341

Shares Held

136M

Call Options Held

348K

Put Options Held

250K

Ra Capital Management, L.P. Boston, MA

12.2M
Shares

$435 Million
9.56% of portfolio
Vanguard Group Inc Valley Forge, PA

12M
Shares

$430 Million
0.01% of portfolio
Janus Henderson Group PLC London, X0

11.8M
Shares

$420 Million
0.25% of portfolio
Black Rock Inc. New York, NY

9.94M
Shares

$355 Million
0.02% of portfolio
Wellington Management Group LLP Boston, MA

6.42M
Shares

$229 Million
0.05% of portfolio

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $2.12B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of 111 Capital, based on Form 13F filings with the SEC.

News

Stay updated on 111 Capital with notifications on news.

Account